303 related articles for article (PubMed ID: 24714565)
21. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
22. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
Moore PL; Williamson C; Morris L
Trends Microbiol; 2015 Apr; 23(4):204-11. PubMed ID: 25572881
[TBL] [Abstract][Full Text] [Related]
23. Polyreactivity and autoreactivity among HIV-1 antibodies.
Liu M; Yang G; Wiehe K; Nicely NI; Vandergrift NA; Rountree W; Bonsignori M; Alam SM; Gao J; Haynes BF; Kelsoe G
J Virol; 2015 Jan; 89(1):784-98. PubMed ID: 25355869
[TBL] [Abstract][Full Text] [Related]
24. Coadministration of CH31 Broadly Neutralizing Antibody Does Not Affect Development of Vaccine-Induced Anti-HIV-1 Envelope Antibody Responses in Infant Rhesus Macaques.
Dennis M; Eudailey J; Pollara J; McMillan AS; Cronin KD; Saha PT; Curtis AD; Hudgens MG; Fouda GG; Ferrari G; Alam M; Van Rompay KKA; De Paris K; Permar S; Shen X
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541851
[TBL] [Abstract][Full Text] [Related]
25. Immune tolerance negatively regulates B cells in knock-in mice expressing broadly neutralizing HIV antibody 4E10.
Doyle-Cooper C; Hudson KE; Cooper AB; Ota T; Skog P; Dawson PE; Zwick MB; Schief WR; Burton DR; Nemazee D
J Immunol; 2013 Sep; 191(6):3186-3191. PubMed ID: 23940276
[TBL] [Abstract][Full Text] [Related]
26. HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design.
Bricault CA; Yusim K; Seaman MS; Yoon H; Theiler J; Giorgi EE; Wagh K; Theiler M; Hraber P; Macke JP; Kreider EF; Learn GH; Hahn BH; Scheid JF; Kovacs JM; Shields JL; Lavine CL; Ghantous F; Rist M; Bayne MG; Neubauer GH; McMahan K; Peng H; Chéneau C; Jones JJ; Zeng J; Ochsenbauer C; Nkolola JP; Stephenson KE; Chen B; Gnanakaran S; Bonsignori M; Williams LD; Haynes BF; Doria-Rose N; Mascola JR; Montefiori DC; Barouch DH; Korber B
Cell Host Microbe; 2019 Jan; 25(1):59-72.e8. PubMed ID: 30629920
[TBL] [Abstract][Full Text] [Related]
27. 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity.
Kobie JJ; Alcena DC; Zheng B; Bryk P; Mattiacio JL; Brewer M; Labranche C; Young FM; Dewhurst S; Montefiori DC; Rosenberg AF; Feng C; Jin X; Keefer MC; Sanz I
PLoS One; 2012; 7(4):e35356. PubMed ID: 22530008
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 neutralizing antibodies: understanding nature's pathways.
Mascola JR; Haynes BF
Immunol Rev; 2013 Jul; 254(1):225-44. PubMed ID: 23772623
[TBL] [Abstract][Full Text] [Related]
29. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
McGuire AT; Glenn JA; Lippy A; Stamatatos L
J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455
[TBL] [Abstract][Full Text] [Related]
30. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.
Wagh K; Bhattacharya T; Williamson C; Robles A; Bayne M; Garrity J; Rist M; Rademeyer C; Yoon H; Lapedes A; Gao H; Greene K; Louder MK; Kong R; Karim SA; Burton DR; Barouch DH; Nussenzweig MC; Mascola JR; Morris L; Montefiori DC; Korber B; Seaman MS
PLoS Pathog; 2016 Mar; 12(3):e1005520. PubMed ID: 27028935
[TBL] [Abstract][Full Text] [Related]
31. Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.
Wiehe K; Bradley T; Meyerhoff RR; Hart C; Williams WB; Easterhoff D; Faison WJ; Kepler TB; Saunders KO; Alam SM; Bonsignori M; Haynes BF
Cell Host Microbe; 2018 Jun; 23(6):759-765.e6. PubMed ID: 29861171
[TBL] [Abstract][Full Text] [Related]
32. Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
Jardine JG; Sok D; Julien JP; Briney B; Sarkar A; Liang CH; Scherer EA; Henry Dunand CJ; Adachi Y; Diwanji D; Hsueh J; Jones M; Kalyuzhniy O; Kubitz M; Spencer S; Pauthner M; Saye-Francisco KL; Sesterhenn F; Wilson PC; Galloway DM; Stanfield RL; Wilson IA; Burton DR; Schief WR
PLoS Pathog; 2016 Aug; 12(8):e1005815. PubMed ID: 27560183
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibodies for HIV-1 prevention.
Julg B; Barouch DH
Curr Opin HIV AIDS; 2019 Jul; 14(4):318-324. PubMed ID: 31082819
[TBL] [Abstract][Full Text] [Related]
34. An HIV-1 Broadly Neutralizing Antibody from a Clade C-Infected Pediatric Elite Neutralizer Potently Neutralizes the Contemporaneous and Autologous Evolving Viruses.
Kumar S; Panda H; Makhdoomi MA; Mishra N; Safdari HA; Chawla H; Aggarwal H; Reddy ES; Lodha R; Kumar Kabra S; Chandele A; Dutta S; Luthra K
J Virol; 2019 Feb; 93(4):. PubMed ID: 30429339
[TBL] [Abstract][Full Text] [Related]
35. Anti-HIV B Cell lines as candidate vaccine biosensors.
Ota T; Doyle-Cooper C; Cooper AB; Huber M; Falkowska E; Doores KJ; Hangartner L; Le K; Sok D; Jardine J; Lifson J; Wu X; Mascola JR; Poignard P; Binley JM; Chakrabarti BK; Schief WR; Wyatt RT; Burton DR; Nemazee D
J Immunol; 2012 Nov; 189(10):4816-24. PubMed ID: 23066156
[TBL] [Abstract][Full Text] [Related]
36. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.
Saunders KO; Verkoczy LK; Jiang C; Zhang J; Parks R; Chen H; Housman M; Bouton-Verville H; Shen X; Trama AM; Scearce R; Sutherland L; Santra S; Newman A; Eaton A; Xu K; Georgiev IS; Joyce MG; Tomaras GD; Bonsignori M; Reed SG; Salazar A; Mascola JR; Moody MA; Cain DW; Centlivre M; Zurawski S; Zurawski G; Erickson HP; Kwong PD; Alam SM; Levy Y; Montefiori DC; Haynes BF
Cell Rep; 2017 Dec; 21(13):3681-3690. PubMed ID: 29281818
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth.
van Schooten J; van Gils MJ
Retrovirology; 2018 Nov; 15(1):74. PubMed ID: 30477581
[TBL] [Abstract][Full Text] [Related]
38. Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design?
Bonsignori M
Expert Rev Vaccines; 2014 Nov; 13(11):1271-3. PubMed ID: 25017952
[TBL] [Abstract][Full Text] [Related]
39. Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials.
Patricia D'Souza M; Allen MA; Baumblatt JAG; Boggiano C; Crotty S; Grady C; Havenar-Daughton C; Heit A; Hu DJ; Kunwar N; McElrath MJ;
Vaccine; 2018 Sep; 36(38):5671-5677. PubMed ID: 30097219
[TBL] [Abstract][Full Text] [Related]
40. Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection Cohort.
Landais E; Huang X; Havenar-Daughton C; Murrell B; Price MA; Wickramasinghe L; Ramos A; Bian CB; Simek M; Allen S; Karita E; Kilembe W; Lakhi S; Inambao M; Kamali A; Sanders EJ; Anzala O; Edward V; Bekker LG; Tang J; Gilmour J; Kosakovsky-Pond SL; Phung P; Wrin T; Crotty S; Godzik A; Poignard P
PLoS Pathog; 2016 Jan; 12(1):e1005369. PubMed ID: 26766578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
